Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 21588 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	2. 20159 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	3. 19834 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	4. 12878 Accesses	Research Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui, Rachelle S Doody Alzheimers Res Ther 2009, 1:7 (21 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Persistent treatment with cholinesterase inhibitors and/or memantine had a positive impact on Alzheimers disease (AD) progression by multiple cognitive and functional outcome measures.
	5. 11009 Accesses	Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nilüfer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
	6. 10664 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	7. 10439 Accesses	Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimers Res Ther 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.
	8. 10435 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	9. 9904 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen et al. Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	10. 9744 Accesses	Review Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare Alzheimer's Research & Therapy 2009, 1:6 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Weller et al. highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies for Alzheimer's disease.
	11. 9679 Accesses	Research A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:29 (15 October 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A Quick Test of cognitive speed is twice as sensitive as the mini-mental state examination in evaluating cholinesterase inhibitor treatment in Alzheimer’s disease patients, indicating its potential usefulness in the primary care setting.
	12. 8596 Accesses	Commentary Alzheimer's disease therapeutic research: the path forward Paul S Aisen Alzheimers Res Ther 2009, 1:2 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Despite recent negative trial results, a clear path forward is emerging in Alzheimer’s disease therapeutic research using newly available tools to allow the study of new treatments at earlier stages in the disease process.
	13. 8319 Accesses	Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimers Res Ther 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
	14. 7195 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	15. 7016 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.
	16. 6654 Accesses	Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
	17. 6606 Accesses	Review Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions Larry G Brooks, David A Loewenstein Alzheimer's Research & Therapy 2010, 2:28 (29 September 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary From mild cognitive impairment through to dementia, Alzheimer’s disease is a continuous process and it is likely that multivariate models incorporating cognitive measures, functional variables and biomarker data are best suited to assess this longitudinal change.
	18. 6526 Accesses	Research A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers, Kaj Blennow Alzheimer's Research & Therapy 2010, 2:7 (29 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta isoforms in cerebrospinal fluid increase during gamma-secretase inhibitor treatment in Alzheimer's disease (AD), and may be used as novel sensitive biomarkers to monitor the biochemical effect in clinical trials.
	19. 6505 Accesses	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	20. 6209 Accesses	Commentary Herbal therapy: a new pathway for the treatment of Alzheimer's disease Jinzhou Tian, Jing Shi, Xuekai Zhang, Yongyan Wang Alzheimer's Research & Therapy 2010, 2:30 (22 October 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary On the basis of current evidence, Tian and colleagues discuss whether herbal therapy could be a novel pathway to treat Alzheimer’s disease (AD) and the implications of these results on future therapy development.
	21. 6138 Accesses	Review Dementia prevention: current epidemiological evidence and future perspective Francesca Mangialasche, Miia Kivipelto, Alina Solomon, Laura Fratiglioni Alzheimer's Research & Therapy 2012, 4:6 (13 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mangialasche and colleagues address current epidemiological research and intervention studies to identify promising preventative strategies for Alzheimer's disease (AD) and dementia; considering the need for randomized controlled trials to confirm these findings.
	22. 6070 Accesses	Review Angiotensins and Alzheimer's disease: a bench to bedside overview Patrick G Kehoe Alzheimers Res Ther 2009, 1:3 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Kehoe proposes angiotensins and associated enzymatic pathways as important mediators of recognized but undefined links between blood pressure and Alzheimer’s disease.
	23. 5987 Accesses	Commentary Can novel therapeutics halt the amyloid cascade? Niels D Prins, Pieter Visser, Philip Scheltens Alzheimer's Research & Therapy 2010, 2:5 (9 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Prins and colleagues discuss the negative results of the recent bapineuzumab and tarenflurbil trials, the lessons learnt from them and comment on the potential implications for future novel therapeutics.
	24. 5894 Accesses	Research Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao Alzheimer's Research & Therapy 2011, 3:8 (15 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stem cell factor and granulocyte-colony stimulating factor limit beta-amyloid accumulation in a mouse model suggesting treatment with hematopoeitic growth factors may offer a new therapeutic approach for Alzheimer’s disease.
	25. 5623 Accesses	Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.